Press releases for 2007
Our latest press releases are available below.
(Please note: Adobe
Acrobat Reader is required to view these files)
07 Dec 2007
Cambridge Laboratories announces Positive Recommendation for
XENAZINE® approval in the US
14 Nov 2007Cambridge Laboratories (“Cambridge”), the privately owned specialty pharmaceutical company, announces today that its distribution partner in Italy, Chiesi Group (“Chiesi”), has now launched Xenazina®
28 August 2007
The Journal of Neuroscience publishes report supporting the action of Cambridge Laboratories’ tetrabenazine in the
treatment of Huntington’s Disease
14 August 2007
Cambridge Laboratories’ XENAZINA® (tetrabenazine)
gains approval in Italy through its partner Chiesi Farmaceutici
11 April 2007
Cambridge has appointed Ashfield Healthcare (“Ashfield”), the specialist sales group, to work with its oncology business unit and maximise the existing market leadership position of ImmuCyst 81mg® and drive continued sales growth of Gelclair®, within the UK.
9 March 2007
Cambridge Laboratories’ announces today that its distribution partner in Germany, Temmler Pharma, has now launched NITOMAN® (tetrabenazine, also known as XENAZINE® in the US and certain other markets) following its approval from the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) on 19 January 2007.
19 February 2007
Cambridge Laboratories announces today that it has divested its interest in nabilone, a treatment for nausea and vomiting associated with cancer chemotherapy, to Valeant Pharmaceuticals International.
14 February 2007
Cambridge Laboratories has announced that it has received marketing approval from the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its drug NITOMAN® (tetrabenazine) in Germany.